Alprazolam
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Alprazolam | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of sedation, respiratory depression |
If coadministering, use lowest effective dose and monitor for alprazolam adverse effects |
|||
| Ritonavir Alprazolam 1097 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | 1 mg x 1 | Alprazolam AUC no significant change; Cmax decreased 16% |
Avoid combination and use alternative agents |
||
| Ritonavir Alprazolam 1096 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Increased alprazolam effects (eg, increased sedation, confusion, respiratory depression) |
1 mg x 1 dose | Alprazolam clearance: decreased 59%; half-life: increased 122% |
Avoid combination and use alternative agents |
|
| Darunavir Alprazolam 991 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential for increased risk of alprazolam adverse effects |
Use alternative agents |
|||
| Elvitegravir Alprazolam 194 | Red: Avoid combination | Do not coadminister: Potential for increased levels of midazolam | Potential for increased alprazolam effects (e.g. sedation, altered mental status, respiratory depression) |
Coadministration of EVG with oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation. |

